Pharmaceutical Intermediates Market Business Growth and Trends to 2028

Pharmaceutical Intermediates Market 2022 Research report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pharmaceutical Intermediates in these regions, from 2022 to 2028 (forecast), covering North America, Europe, Asia Pacific, Middle East & Africa, South & Central America.

Pharmaceutical Intermediates Market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 4.2% from 2022-2028.

Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00005559/?utm_source=OpenPR&utm_medium=10376

Antibiotic intermediates are products that are used to produce antibiotics. For instance, 7- aminodeacetoxy-cephalosporanic acid intermediate which is used to manufacture of semi-synthetic cephalosporins. Similarly, 6- aminopenicillanic acid is an intermediate used to manufacture of semi-synthetic penicillins. Antibiotics are antimicrobial medicines that kill or prevent the growth of bacterial infections in humans as well as animals. These can be taken orally, topically and intravenously (I.V).
The segment is expected to witness rapid growth owing to rising prevalence of infectious diseases and government support for antibiotics to eradicate infectious diseases. Additionally, an increase in antibiotic resistance infections is expected to demand development of novel drugs.

Countries in Asia Pacific are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Low manufacturing and operating costs in China and India are key factors driving the pharmaceutical manufacturing business in the region. Recent growth in the pharmaceutical industry in both these countries indicate a positive outlook for the pharmaceutical intermediates market. As per the India Brand Equity Foundation (IBEF), an initiative of the Ministry of Commerce & Industry of the Government of India, the value of the pharmaceutical industry in India is expected to reach US$ 100 billion by 2025. Moreover, pharmaceuticals export from India was worth US$ 16.3 billion in 2020; these exports include drug formulations, bulk drugs, intermediates, biologicals, and herbal products.

Flourishing domestic pharmaceutical market in APAC and increasing number of pipeline drugs are further opening new avenues for the contract manufacturers as well as generic drug manufacturing in the region. As per IBEF, India's domestic pharmaceutical market business revenue reached US$ 20.03 billion (INR 1.4 lakh crore) in 2019, with a year-on-year (y-o-y) increase of 9.8% from US$ 18.12 billion (INR 129,015 crore) in 2018. Additionally, to meet the growing demand, many contract-based organizations are expanding their manufacturing capabilities, further boosting the growth of the market. For instance, in January 2020, STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, opened a new large-scale oligonucleotide API manufacturing facility in China. Thus, the emerging markets hold high potential and huge revenue generation opportunities for the pharmaceutical continuous manufacturing companies.

The Pharmaceutical Intermediates market majorly consists of the players such as companies such Pfizer, Inc, Dishman Group, Dextra Laboratories Limited, Sanofi Winthrop Industries S.A., Vertellus Holdings LLC, BASF SE, Lianhetech, Codexis, Midas Pharma GmbH and Chiracon GmbH. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market.

The companies have utilized organic strategies such as launches, expansion, and product approvals. Whereas, the inorganic strategies such as mergers & acquisitions, partnership, collaborations, were widely seen in the Pharmaceutical Intermediates market.
Several in organic approaches, such as product launches, and expansion in the Pharmaceutical Intermediates market, have resulted in the positive growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have help the company to strengthen its revenue, which allows the company to hold a strong position in the market.

Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00005559/?utm_source=OpenPR&utm_medium=10376

Contact us:

If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About The Insight Partners:

The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.

This release was published on openPR.